Inventor · disambiguated record
Rudolf Widmann
Also filed as: WIDMANN RUDOLF · WIDMANN RUDOLF STEFAN
6 granted patents·9 pending applications·11 citations·filing 2002–2022
74Inventor score
Files withAOP ORPHAN PHARMACEUTICALS AG12FEDERAL MOGUL FRIEDBERG GMBH1LIN KO-CHUNG1ORPHA SWISS GMBH1
Top patents by PatentIndex Score
15 records- 0176US2023277674A1Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonistsAOP ORPHAN PHARMACEUTICALS AG·Filed 2022·Application pending·0 cites
- 0271US11963940B2Parenteral esmolol formulationAOP ORPHAN PHARMACEUTICALS AG·Filed 2022·Granted Apr 23, 2024·0 cites·10 claims
- 0369US10660964B2Pharmaceutical composition for the parenteral administration of ultrashort-effective beta-adrenoreceptor antagonistsAOP ORPHAN PHARMACEUTICALS AG·Filed 2018·Granted May 26, 2020·0 cites·8 claims
- 0468US11517624B2Pharmaceutical composition for the parenteral administration of ultrashort-effective β-adrenoreceptor antagonistsAOP ORPHAN PHARMACEUTICALS AG·Filed 2020·Granted Dec 6, 2022·0 cites·12 claims
- 0564US8617532B2Therapeutic use of interferon-polymer conjugatesLIN KO-CHUNG·Filed 2010·Granted Dec 31, 2013·1 cites·10 claims
- 0661US2010311738A1Pharmaceutical Composition For The Parenteral Administration Of Ultrashort-Effective Beta-Adrenoreceptor AntagonistsAOP ORPHAN PHARMACEUTICALS AG·Filed 2008·Application pending·0 cites
- 0756US6726216B2Piston ring with oxide-nitride composite layerFEDERAL MOGUL FRIEDBERG GMBH·Filed 2002·Granted Apr 27, 2004·10 cites·4 claims
- 0852US2016361422A1Pharmaceutical Composition for the Parenteral Administration of Ultrashort-Effective Beta-Adrenoreceptor AntagonistsAOP ORPHAN PHARMACEUTICALS AG·Filed 2016·Application pending·0 cites
- 0950US2015087704A1Parenteral esmolol formulationAOP ORPHAN PHARMACEUTICALS AG·Filed 2013·Application pending·0 cites
- 1050US2015086637A1Novel composition for treatment of essential thrombocythemiaAOP ORPHAN PHARMACEUTICALS AG·Filed 2014·Application pending·0 cites
- 1148US9782413B2Composition for treatment of essential thrombocythemiaAOP ORPHAN PHARMACEUTICALS AG·Filed 2016·Granted Oct 10, 2017·0 cites·9 claims
- 1248US2017326095A1Parenteral esmolol formulationAOP ORPHAN PHARMACEUTICALS AG·Filed 2017·Application pending·0 cites
- 1346US2018028538A1Novel composition for treatment of essential thrombocythemiaAOP ORPHAN PHARMACEUTICALS AG·Filed 2017·Application pending·0 cites
- 1443US2011144117A1Pharmaceutical Dosage Form Containing TetrahydrobiopterinORPHA SWISS GMBH·Filed 2009·Application pending·0 cites
- 1542US2013028945A1Novel composition for treatment of essential thrombocythemiaAOP ORPHAN PHARMACEUTICALS AG·Filed 2011·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →